3SBio stock
Price history
−60.77% over the period1 year: from $32.40 (November 20, 2025) to $12.71 (November 20, 2026), −60.77%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $12.71 |
| October 30, 2026 | $13.54 |
| September 30, 2026 | $16.57 |
| August 31, 2026 | $16.12 |
| July 31, 2026 | $16.72 |
| June 30, 2026 | $16.89 |
| May 29, 2026 | $18.50 |
| April 30, 2026 | $23.14 |
| March 31, 2026 | $22.64 |
| February 27, 2026 | $21.94 |
| January 30, 2026 | $23.30 |
| December 31, 2025 | $24.26 |
| November 28, 2025 | $31.26 |
| November 20, 2025 | $32.40 |
At a glance
The company
Develops, produces and sells biopharmaceutical products for treating conditions including thrombocytopenia, anemia, rheumatoid arthritis, and cancer in China and internationally
Latest results
Quarter to June 30, 2026 · EPS ¥0.44
Next event
TickerLandia's take on 3SBio
- Cheaper than similar companies: trailing 12-month P/E 3.9 vs 44 (−91%) in a group of 7.
- Strong point: Profitability (89/100 in its group). Weak point: Market momentum (16/100).
- “Beaten down but solid” (Hong Kong): No. 6 of 28.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−62.86% from the 52-week high
Analysts · 14 analysts
Average target$28.90+127.40% vs. price
Buy 13 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: 3SBio
Compared with similar companies: very low price, very high profitability, and very weak momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery low5
How much it costs relative to what it produces.
Metric Value Position in group Price/book 1.13 6 P/E (trailing 12 months) 3.90 6 EV/EBITDA 2.11 4 Forward P/E 10.6 8 Price/sales 2.00 1 Profitabilityvery high89
How much it earns on revenue and capital.
Metric Value Position in group Net margin 46.3% 89 Operating margin 60.3% 96 Gross margin 91.9% 78 ROA 22.7% 96 ROE 35.9% 84 Earnings stabilityhigh72
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 13.9% 61 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage44
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −20.80% 44 Revenue growth (year over year) +3.90% 20 Average revenue growth (3 years) +37.11% 68 Financial strengthhigh74
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.05 66 Current ratio 6.06 75 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.87 78 Interest coverage 137.3 79 Dividendaverage47
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 6.8% 3 Dividend yield 1.7% 81 Consecutive dividend years 5 years 57 Market momentumvery weak16
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −11.67% 27 Relative strength (6 months) −24.55% 17 1-year return −60.77% 1 Distance from 200-day average −31.55% 18 Riskhigh75
How much the price swings.
Metric Value Position in group Beta (1 year) 1.26 75 Volatility (60 days) 45.5% 65 Maximum drawdown (12 months) 60.8% 86
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
3SBio is cheaper than similar companies
3SBio's P/E (trailing 12 months): 3.90, −91% against the median of a group of 7 similar companies (44.1).
Compared with 7 similar companies
| Metric | 3SBio | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 3.90 | Low | |
| Forward P/E | 10.6 | Low | |
| Operating margin | 60.3% | High | |
| ROE | 35.9% | High | |
| Debt/equity | 0.05 | Middle |
Grey band: the middle half of the group; tick: the median; dot: 3SBio. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥4.53B
Latest quarter · Q2 2026
Net income
¥1.15B
Latest quarter · Q2 2026
Quarterly net margin
25.3%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $35.76B
- P/E
- 3.9
- EPS
- $3.70
- Volume
- 11.42M
- Daily trading
- €26.61M
- Dividend yield
- 1.97%
- Last ex-dividend on July 21, 2026
How 3SBio is changing
All resultsRevenue grew 25.9% a year on average over the last 5 years
Operating margin rose from 27.9% to 59.3%
Profits turn into cash: free cash flow equal to 109% of net income
Returns
3SBio returns with dividends
$1,000 invested in 3SBio 5 years ago, on November 22, 2021, would be worth $2,047 today with dividends reinvested: +104.72% in total, +15.43% per year. On price alone it would be $1,845 (+84.47%).
| Period | 3SBio | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −13.54% | −6.10% | $865 |
| 6 months | −34.08% | −12.63% | $659 |
| Year to date | −47.61% | −12.56% | $524 |
| 1 year | −60.19% | −13.26% | $398 |
| 3 years | +89.99% | +26.06% | $1,900 |
| 5 years | +104.72% | −10.18% | $2,047 |
| 10 years | +55.00% | +0.24% | $1,550 |
Over the last 6 months it has done better than 7% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment
The chart in detail
3SBio: technical analysis
3SBio is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 64.6% below its all-time closing high ($35.90, September 9, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 30
- Between 30 and 70
- vs 200-session average
- −31.55%
Active signals
New 52-week low.
since November 19, 2026
Close below the low of the previous 55 sessions.
Support and resistance
Price areas where 3SBio has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$16.18+27.30%2 touches, last on August 21, 2026
- Resistance$15.56+22.40%4 touches, last on November 6, 2026
- Resistance$14.97+17.78%3 touches, last on October 21, 2026
- Last price$12.71
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.26
- Volatility (60 sessions, annualised)
- 45.5%
- Largest fall in the last year
- −60.77%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
3SBio: seasonality
Average monthly price change over 12 years
Over the last 12 years, the strongest month for 3SBio has been March: +11.32% on average, positive in 9 years out of 11. The weakest has been December: −4.45% on average, positive in 5 years out of 11. November, the current month, has been positive in 8 years out of 11 (+5.99% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.66% | −0.82% | 5 of 11 |
| February | +0.06% | −0.92% | 5 of 11 |
| March | +11.32% | +3.23% | 9 of 11 |
| April | −1.11% | 0.00% | 5 of 11 |
| May | +8.09% | +4.24% | 7 of 11 |
| June | +2.09% | +5.01% | 7 of 11 |
| July | −4.00% | −4.82% | 1 of 12 |
| August | −1.59% | −3.49% | 4 of 12 |
| September | +2.75% | +2.84% | 8 of 12 |
| October | −3.20% | −3.73% | 5 of 12 |
| November | +5.99% | +4.31% | 8 of 11 |
| December | −4.45% | −2.55% | 5 of 11 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
3SBio and its competitors
TPIAO, EPIAO, Yisaipu, Cipterbin and Mandi are the names people most associate with 3SBio Inc. Its biopharmaceutical portfolio addresses low platelet counts, anemia linked to chronic kidney disease, rheumatoid arthritis, psoriasis, breast cancer and hair loss. Beyond drug development and production, the group sells pharmaceuticals, operates pharmaceutical retail, and provides clinic, technology, agricultural and consulting services. Its activities reach the Chinese market, the United States and other countries.
- Headquarters
- Shenyang, China
- Employees
- 6,068
- Founded
- 1993
- Chief executive
- Jing Lou
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| 3SBio1530 | $4.56B | 60.3% | 3.90 | −34.08% |
| Akeso9926 | $6.81B | -30.7% | — | −50.70% |
| Telix PharmaceuticalsTLX | $2.92B | 6.2% | 92.3 | −7.71% |
| InSilico Medicine Cayman TopCo3696 | $2.59B | -6.9% | — | −36.46% |
| Genscript Biotech1548 | $8.77B | 14.9% | — | +112.07% |
| Haisco Pharmaceutical Group002653 | $8.97B | 21.1% | 44.1 | +0.54% |
Same industry or related industries, similar size. Compare 3SBio with its competitors · Full profile
